Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J. Fu W, et al. Among authors: chim cs. Ann Hematol. 2025 May;104(5):2765-2776. doi: 10.1007/s00277-025-06303-3. Epub 2025 May 23. Ann Hematol. 2025. PMID: 40407887 Free PMC article. Clinical Trial.
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study.
Kim K, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim CS, Nawarawong W, Siritanaratkul N, Durie BG. Kim K, et al. Among authors: chim cs. Am J Hematol. 2014 Jul;89(7):751-6. doi: 10.1002/ajh.23731. Epub 2014 Apr 26. Am J Hematol. 2014. PMID: 24723430 Free article.
Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.
Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, Duarte GO, Fantl DB, Navarro JR, Conte G, Gomez-Almaguer D, Ruiz-Argüelles GJ, Kim K, Shimizu K, Chen W, Huang SY, Chng WJ, Chim CS, Nawarawong W, Durie B. Hungria VTM, et al. Among authors: chim cs. Ann Hematol. 2019 Apr;98(4):941-949. doi: 10.1007/s00277-019-03602-4. Epub 2019 Feb 6. Ann Hematol. 2019. PMID: 30729281
Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Lin TL, Chim CS, Qi M, Wang J, Lu X, Song Y, Jia B, Yang X, Liu W, Zhou T, Yin L, Li Y, Zhang R, Hou J, Wang J. Fu W, et al. Among authors: chim cs. Clin Lymphoma Myeloma Leuk. 2023 Jun;23(6):446-455.e4. doi: 10.1016/j.clml.2023.02.009. Epub 2023 Mar 4. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37024420 Free article. Clinical Trial.
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J. Fu W, et al. Among authors: chim cs. Ann Hematol. 2025 Jan;104(1):515-525. doi: 10.1007/s00277-024-05958-8. Epub 2024 Sep 4. Ann Hematol. 2025. PMID: 39227450 Free PMC article. Clinical Trial.
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J. Fu W, et al. Among authors: chim cs. Ann Hematol. 2024 Nov;103(11):4835-4836. doi: 10.1007/s00277-024-06020-3. Ann Hematol. 2024. PMID: 39311958 Free PMC article. No abstract available.
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.
Chen W, Cai Z, Chim CS, Chng WJ, Du J, Fu C, Gao W, Hanamura I, Hou J, Huang JS, Ishida T, Li C, Liu A, Ptushkin V, Takezako N, Wong RSM, Yoon DH. Chen W, et al. Among authors: chim cs. Clin Hematol Int. 2025 Aug 8;7(3):36-59. doi: 10.46989/001c.141401. eCollection 2025. Clin Hematol Int. 2025. PMID: 40786241 Free PMC article. Review.
Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China.
Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J 4th, Xiao JH, Orlowski R, Chim CS. Lu J, et al. Among authors: chim cs. Leuk Lymphoma. 2016 Jul;57(7):1534-8. doi: 10.3109/10428194.2015.1135434. Epub 2016 Feb 17. Leuk Lymphoma. 2016. PMID: 26887657
267 results